9 Meters Biopharma, Inc.

NasdaqCM:NMTR Stock Report

Mkt Cap: US$28.2m

9 Meters Biopharma Future Growth

How is 9 Meters Biopharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


47.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqCM:NMTR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202538-1818163
12/31/20249-58-36-423
12/31/2023N/A-50-45-496
9/30/2022N/A-41-35-35N/A
6/30/2022N/A-46-36-34N/A
3/31/2022N/A-43-36-33N/A
12/31/2021N/A-37-32-29N/A
9/30/2021N/A-32-30-28N/A
6/30/2021N/A-27-24-24N/A
3/31/2021N/A-63-26-23N/A
12/31/2020N/A-61-23-19N/A
9/30/2020N/A-65-19-16N/A
6/30/2020N/A-66-19-16N/A
3/31/2020N/A-26-16-16N/A
12/31/2019N/A-27-18-18N/A
9/30/2019N/A-22-17-17N/A
6/30/2019N/A-14-17-17N/A
3/31/2019N/A-14-12-12N/A
12/31/2018N/A-24-15-15N/A
9/30/2018N/A-22-15-15N/A
6/30/2018N/A-24-12-12N/A
3/31/2018N/A-23-11-11N/A
12/31/2017N/A-12-5-5N/A
9/30/2017N/A-11-4-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NMTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NMTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NMTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NMTR is forecast to have no revenue next year.

High Growth Revenue: NMTR is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NMTR's Return on Equity is forecast to be high in 3 years time


Discover growth companies